In most patients with EGFR‑mutant lung cancer, modern targeted medicines such as osimertinib work remarkably well. They can keep the cancer under control for several years, often with minimal symptoms and a good quality of life. Yet in a small group of patients — about 10 to 15 percent — the cancer can change its behaviour over time. Instead of growing in the same predictable way, it can transform into a more aggressive form known as small‑cell lung cancer. This is called small‑cell transformation and, while uncommon, it is one of the most important resistance patterns we see in EGFR‑mutant disease.
Understanding why this happens
Every cancer contains many different cell populations. Even when treatment is effective, a few cells may survive and adapt under pressure. In EGFR‑mutant disease, some of these surviving cells can “switch identity” and start behaving like small‑cell lung cancer. This does not mean the original diagnosis was wrong — it reflects how adaptable cancer cells can be.
How transformed disease differs from typical small‑cell lung cancer
In people with a smoking history, small‑cell lung cancer usually develops de novo and carries a high mutation burden — meaning the DNA has many changes. These tumours are often more visible to the immune system, which is one reason immunotherapy can work relatively well.
When small‑cell transformation arises from an EGFR‑mutant cancer, the mutation burden is usually lower. The biology remains influenced by the original EGFR pathway, making the tumour less visible to immune surveillance. Practically, this often means that immunotherapy is less effective after transformation than it is in typical smoking‑related small‑cell lung cancer.
Can transformation be prevented?
There has been strong interest in whether early or combined treatment could prevent this change. At Memorial Sloan Kettering, Dr Helena Yu and colleagues explored adding platinum‑based chemotherapy to targeted therapy early in treatment, hoping to eliminate the small subset of cells with potential to transform later. These studies did not show meaningful benefit in preventing transformation or extending survival. For now, prevention strategies have not changed standard practice.
How we detect it
The first clue is usually clinical: a patient who has been doing well on EGFR‑targeted therapy suddenly deteriorates, develops new symptoms, or shows rapid progression on scans after a long period of stability. The only reliable way to confirm transformation is through a repeat biopsy. This allows pathologists to look directly at the cancer cells and perform updated molecular testing to guide the next step in treatment.
Treatment approach
Once small‑cell transformation is confirmed, treatment generally follows the same principles used for small‑cell lung cancer — typically platinum‑based chemotherapy (for example, carboplatin and etoposide). Some centres consider re‑introducing targeted therapy later, depending on the molecular profile and clinical course. The goal is to regain disease control quickly and maintain quality of life.
What patients can do
Stay proactive and engaged. Report new or rapidly changing symptoms early and keep to scheduled scans and reviews. Early recognition allows the team to act quickly if transformation is suspected, helping to maintain control for as long as possible.